RxDoctor Payments Data

Lyudmila Dekhovich, DO

Family Medicine · Brooklyn, NYNPI 1013445998

Payments from drug & device makers

$2,175in general payments, 2019–2025

Across 95 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$642
  • Johnson & Johnson$197
  • GSK$196
  • Boehringer Ingelheim$173
  • Argenx US, Inc.$167
  • Amarin Pharma, Inc.$128
  • plus $672 from 20 others

What the payments were for

  • Food & beverage$2,175100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,175 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$85,441
Medicare patients
224
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$53,743
OzempicSemaglutide23$24,120
JanuviaSitagliptin Phosphate24$22,714
VascepaIcosapent Ethyl50$16,316
CreonLipase/Protease/Amylase21$15,916
ZenpepLipase/Protease/Amylase18$14,730
LinzessLinaclotide17$13,747
XiidraLifitegrast11$7,351
TrulancePlecanatide13$6,416
Breo ElliptaFluticasone/Vilanterol12$4,986
Dexlansoprazole DrDexlansoprazole24$4,487
SymbicortBudesonide/Formoterol Fumarate17$3,293
Atorvastatin Calcium298$2,918
Rosuvastatin Calcium206$2,856
SynthroidLevothyroxine Sodium41$2,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$53,74372 claims
AbbVieCreon, Linzess, Synthroid$642$32,09779 claims
Novo NordiskOzempic$56$24,12023 claims
MerckJanuvia$29$22,71424 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$49$6,41613 claims
GSKBreo Ellipta$196$4,98612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →